- Home
- Products
- Customized ADCs
- TPBG
- Anti-TPBG (clone H8)-Amide-CalichDMH ADC
Anti-TPBG (clone H8)-Amide-CalichDMH ADC (CAT#: ADC-W-199)
This ADC product is comprised of an anti-TPBG monoclonal antibody (clone H8) conjugated via a Amide linker to CalichDMH. The CalichDMH is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, CalichDMH binds to DNA, causes DNA damage.
- Product Information
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Antibody clone #
- Murine H8 Antibody
- Name
- TPBG
- Alternative Names
- M6P1; TPBGAG; WAIF1; TPBG oncofetal antigen; TPBG oncotrophoblast glycoprotein; wnt-activated inhibitory factor 1; TPBG oncofetal trophoblast glycoprotein;
- Target Entrez Gene ID
- 7162
- Target UniProt ID
- Q13641
- Overview
- This gene encodes a leucine-rich transmembrane glycoprotein that may be involved in cell adhesion. The encoded protein is an oncofetal antigen that is specific to trophoblast cells. In adults this protein is highly expressed in many tumor cells and is associated with poor clinical outcome in numerous cancers. Alternate splicing in the 5 UTR results in multiple transcript variants that encode the same protein.
- Overview
- Anti-TPBG antibody, clone # Murine H8
- Clone #
- Murine H8 Antibody
- Host animal
- Mouse
- Species Reactivity
- Human
- Name
- Amide (4-mercapto-4-methyl-pentanoic acid)
- Description
- Acid-labile linkers, belonging to chemically cleavable linkers, are designed based on a pH-dependent release mechanism and remain intact during systemic circulation in the blood's neutral pH environment (pH 7.3–7.5) but to undergo hydrolysis and release drug once the ADC is internalized into mildly acidic endosomal (pH 5.0–6.5) and lysosomal (pH 4.5–5.0) compartments of the cell.
- Name
- CalichDMH (Calicheamicin (CM))
- Description
- Calicheamicin,produced by prokaryotic microorganisms, are a group of DNA cleaving agents with similar structure that binds in the minor grove of DNA in a relatively sequence-specific manner.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-IL9 (Enokizumab)-MC-MMAF ADC (CAT#: ADC-W-1450)
- Anti-SOST (Romosozumab)-MC-MMAF ADC (CAT#: ADC-W-1774)
- Anti-CD37 (Otlertuzumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-822)
- Anti-CD22 (Moxetumomab pasudotox)-SPDB-DM4 ADC (CAT#: ADC-W-801)
- Anti-ERBB2 (Trastuzumab-HC-P127)-DBCO-MMAF ADC (CAT#: ADC-W-247)
- Anti-TPBG (clone A1)-VC-MMAE ADC (CAT#: ADC-W-002)
- Anti-TM4SF1 ( clone v1.10)-Mc-LP2 ADC (CAT#: ADC-W-517)
- Anti-CCR4 (Mogamulizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-763)
- Anti-HLA-DRB1 (Apolizumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1206)
- Anti-IGF1R (Cixutumumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1248)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-199. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-163 | Anti-TPBG (K392C)-Mc-MMAD ADC | Mc (maleimidocaproyl) | MMAD (monomethyl auristatin D) |
ADC-W-008 | Anti-TPBG (clone A1)-AcBut-calicheamicin ADC | AcBut [-(4' acetyl phenoxy) butanoic acid] | calicheamicin |
ADC-W-197 | Anti-TPBG (clone H8)-AcBut-CalichDMH ADC | AcBut (4-(4'acetylphenoxy)butanoic acid) | CalichDMH (Calicheamicin (CM)) |
ADC-W-198 | Anti-TPBG (clone H8)-AcPac-CalichDMH ADC | AcPac (3-acetylphenyl acidic acid) | CalichDMH (Calicheamicin (CM)) |
ADC-W-537 | Anti-TPBG-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
CAT# | Product Name | Linker | Payload |
ADC-W-198 | Anti-TPBG (clone H8)-AcPac-CalichDMH ADC | AcPac (3-acetylphenyl acidic acid) | CalichDMH (Calicheamicin (CM)) |
ADC-W-197 | Anti-TPBG (clone H8)-AcBut-CalichDMH ADC | AcBut (4-(4'acetylphenoxy)butanoic acid) | CalichDMH (Calicheamicin (CM)) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.